Stockscreener 앱 받기
0.06
0.00%
0.00
시간 외 거래:
.06
전일 마감가:
$0.06
열려 있는:
$0.055
하루 거래량:
21,171
Relative Volume:
2.30
시가총액:
$N/A
수익:
$3,000
순이익/손실:
$-23.55M
주가수익비율:
-0.0492
EPS:
-1.2183
순현금흐름:
$-19.75M
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+62.16%
1년 성능:
-82.22%
1일 변동 폭
$0.055
$0.06
1주일 범위
$0.055
$0.06
52주 변동 폭
$0.0003
$0.34
Nkgen Biotech Inc Stock (NKGN) Company Profile
Compare NKGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.06 | 0 | 3,000 | -23.55M | -19.75M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nkgen Biotech Inc 주식(NKGN)의 최신 뉴스
NKGen Biotech Expands Convertible Financing Through New Agreement - The Globe and Mail
NKGen Biotech (NKGN) takes $2.42M note, lifts consideration shares - Stock Titan
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
NKGen Biotech Expands Financing Through New Convertible Loan - TipRanks
NKGen Biotech (NKGN) expands AlpineBrook convertible deal with $412.5K note and new warrant - Stock Titan
Nkgen Biotech expands clinical trial site network for Alzheimer’s disease program across US - marketscreener.com
Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US - TradingView
NKGen Biotech Inc. is expanding its Alzheimer’s disease clinical trial site network nationwide across the United States. - Bitget
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment - marketscreener.com
New Alzheimer’s trial sites move NK cell therapy closer to East Coast patients - Stock Titan
Number of shareholders of NKGen Biotech Inc. – OTC:NKGN - TradingView
NKGen Biotech Secures Additional Convertible Financing and Warrants - TipRanks
NKGen Biotech (NKGN) expands dilutive note deal with 12M+ shares, warrant - Stock Titan
NKGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NKGen Biotech Announces Major Convertible Financing and Governance Shift - TipRanks
NKGen Biotech (NKGN) inks $39,922,134.22 secured convertible loan and control rights - Stock Titan
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit - marketscreener.com
NKGen Biotech to Present Troculeucel Mechanism Data in - GlobeNewswire
Former Bio Firm Executive Charged for Insider Trading on Drug Approval Tip - Seoul Economic Daily
NKGen reports cognitive stability in moderate Alzheimer’s trial By Investing.com - Investing.com Australia
NKGen reports cognitive stability in moderate Alzheimer’s trial - Investing.com
As of January 31, 2026, the latest financial data disclosed by Western Asset Municipal High Income Fund Inc shows that its total net asset value has reached 154.63 millions USD. - Bitget
NKGen Biotech Inc. (hereinafter referred to as NKGen Biotech) announced the integrated Phase 1 clinical trial data for its candidate therapy Troculeucel at the Ad/Pd 2026™ conference. - Bitget
NKGen Biotech Reports Combined Phase 1 Troculeucel Data - GlobeNewswire
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™ - Yahoo Finance
Troculeucel Linked to Plasma GFAP Changes and Cognitive Measures in Early Alzheimer Disease Studies - NeurologyLive
NKGen Biotech Korea Co., Ltd.: Dividend historical data and projections - marketscreener.com
Troculeucel may boost cognition, new Alzheimer’s data shows - Longevity.Technology
NKGen to present Alzheimer’s therapy data at AD/PD conference - Investing.com India
NKGen to present Alzheimer’s therapy data at AD/PD conference By Investing.com - Investing.com Canada
NKGen Biotech to Present Integrated Phase 1 Clinical and - GlobeNewswire
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026 - Yahoo Finance
Net income of NKGen Biotech Inc. – OTC:NKGNW - TradingView
NKGen Biotech Secures Additional Debt Financing from AlpineBrook - TipRanks
Nkgen Biotech amends loan agreement to secure additional $343,000 funding - Investing.com
NKGen Biotech Adds $343,000 via Fourth Amendment to AlpineBrook Secured Note; Principal Now $27.1M - TradingView
NKGen Biotech (NKGN) adds $343,000 under AlpineBrook note - Stock Titan
NKGen Biotech, Inc. and NKGen Operating Biotech, Inc. Enter Amendment to Secured Promissory Note Increases Loan Principal and Funding - marketscreener.com
NKGNNKGen Biotech Inc Latest Stock News & Market Updates - Stock Titan
NKGen Biotech increases loan principal by $251,000 under amended agreement By Investing.com - Investing.com Nigeria
NKGen Biotech increases loan principal by $251,000 under amended agreement - Investing.com South Africa
NKGen Biotech expands debt financing with loan amendment - TipRanks
NKGen Biotech Signs Amendment to Secured Promissory Note With AlpineBrook Capital - TradingView
Pre-Market Top Gainer: NKGNW NKGen Warrants NASDAQ $0.0301 Feb 2026: key setup - Meyka
Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ) - Defense World
NKGen Biotech amends loan agreement and extends forward purchase deal By Investing.com - Investing.com Nigeria
NKGen Biotech amends loan agreement and extends forward purchase deal - Investing.com
NKGen Biotech Signs Multiple Financing Agreements - TradingView
NKGen Biotech Secures Additional Funding via Note Amendment - TipRanks
Nkgen Biotech Inc (NKGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.04%
0.76%
자본화:
|
볼륨(24시간):